KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Short-term Investments (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Short-term Investments data on record, last reported at $1.5 billion in Q1 2025.

  • For Q1 2025, Short-term Investments rose 50.65% year-over-year to $1.5 billion; the TTM value through Mar 2025 reached $1.5 billion, up 50.65%, while the annual FY2024 figure was $1.5 billion, 82.09% up from the prior year.
  • Short-term Investments reached $1.5 billion in Q1 2025 per VRTX's latest filing, down from $1.5 billion in the prior quarter.
  • Across five years, Short-term Investments topped out at $1.5 billion in Q4 2024 and bottomed at $274.5 million in Q4 2022.
  • Average Short-term Investments over 5 years is $894.4 million, with a median of $818.0 million recorded in 2023.
  • Peak YoY movement for Short-term Investments: crashed 62.39% in 2022, then soared 209.36% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $729.9 million in 2021, then plummeted by 62.39% to $274.5 million in 2022, then skyrocketed by 209.36% to $849.2 million in 2023, then surged by 82.09% to $1.5 billion in 2024, then dropped by 1.28% to $1.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $1.5 billion in Q1 2025, $1.5 billion in Q4 2024, and $1.3 billion in Q3 2024.